Lineage Cell Therapeutics, Inc. Restricted Cash, Noncurrent
Lineage Cell Therapeutics, Inc. (LCTX) had Restricted Cash, Noncurrent of $562.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashNoncurrent · last filed 2026-08-06
- 2026-06-30: Restricted Cash, Noncurrent $562.00K.
- 2026-03-31: Restricted Cash, Noncurrent $537.00K.
- 2025-12-31: Restricted Cash, Noncurrent $533.00K.
- 2025-09-30: Restricted Cash, Noncurrent $514.00K.
| Period end | Restricted Cash, Noncurrent |
|---|---|
| 2026-06-30 | $562.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $537.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $533.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $514.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $504.00K 10-Q · filed 2026-08-06 |
| 2025-03-31 | $456.00K 10-Q · filed 2026-05-12 |
| 2024-12-31 | $565.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $556.00K 10-Q · filed 2025-11-06 |
| 2024-06-30 | $548.00K 10-Q · filed 2025-08-12 |
| 2024-03-31 | $546.00K 10-Q · filed 2025-05-13 |
| 2023-12-31 | $550.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $526.00K 10-Q · filed 2024-11-14 |
| 2023-06-30 | $562.00K 10-Q · filed 2024-08-08 |
| 2023-03-31 | $570.00K 10-Q · filed 2024-05-09 |
| 2022-12-31 | $581.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $545.00K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $504.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |